{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-347957","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2026-08-13T12:15:15+00:00","discovered_at":"2026-08-13T12:20:03.845897+00:00","generated_at":"2026-08-13T12:20:17.227512+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Candel Q2 net loss $38.9M; BLA for prostate cancer drug planned Q4 2026","bullets":["Net loss $38.9M in Q2 2026 vs $4.8M in Q2 2025, including $12.2M net other expense from warrant liabilities.","R&D expenses $19.8M (vs $7.0M YoY); G&A $6.9M (vs $4.2M YoY).","Cash and equivalents $201.6M as of June 30, 2026; expected to fund operations into Q1 2028.","BLA submission for aglatimagene in localized prostate cancer planned Q4 2026; potential U.S. launch in 2027 if approved.","Phase 3 data in The Lancet Oncology showed 39% improvement in PCa-specific DFS at 58 months; Mark Sims appointed CCO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-347957","json":"https://secwatch.observer/filing/0001193125-26-347957.json","markdown":"https://secwatch.observer/filing/0001193125-26-347957.md","text":"https://secwatch.observer/filing/0001193125-26-347957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/0001193125-26-347957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T12:20:17.227512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}